Cover Image
市場調查報告書

電位依賴性鈣離子通道α2/delta1次單元(CACNA2D1):開發中產品分析

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 368717
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
電位依賴性鈣離子通道α2/delta1次單元(CACNA2D1):開發中產品分析 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 52 Pages
簡介

本報告提供以電位依賴性鈣離子通道α2/delta1次單元(CACNA2D1)為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

電位依賴性鈣離子通道α2/delta1次單元(CACNA2D1) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • 第一三共
  • Intellipharmaceutics International Inc.
  • Mapi Pharma Ltd.
  • Pfizer Inc.
  • Prismic Pharmaceuticals, Inc.
  • Yuhan Corporation

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0432TDB

Summary

Global Markets Direct's, 'Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016', provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics.

The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
  • The report reviews Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview
  • Therapeutics Development
    • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Stage of Development
    • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Therapy Area
    • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Indication
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Companies
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Companies Involved in Therapeutics Development
    • Daiichi Sankyo Company, Limited
    • Intellipharmaceutics International Inc.
    • Mapi Pharma Ltd.
    • Pfizer Inc.
    • Prismic Pharmaceuticals, Inc.
    • Yuhan Corporation
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Drug Profiles
    • (palmidrol + pregabalin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gabapentin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVA-1309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin IR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin XR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Dormant Projects
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Discontinued Products
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Featured News & Press Releases
    • Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules
    • Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain
    • Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica
    • Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate
    • Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia
    • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
    • Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
    • Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective
    • Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting
    • Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin
    • Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release)
    • Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China
    • Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case
    • Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion
    • Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Pipeline by Intellipharmaceutics International Inc., H2 2016
  • Pipeline by Mapi Pharma Ltd., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
  • Pipeline by Yuhan Corporation, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top